Used in the treatment of Parkinson’s disease, this compound acts as a dopamine agonist, specifically targeting D2 and D3 dopamine receptors in the brain. It helps manage motor symptoms such as tremors, stiffness, and bradykinesia by mimicking the action of dopamine, which is deficient in Parkinson’s patients. The compound is particularly valued for its selectivity and sustained activity, allowing for lower dosing frequency and reduced side effects compared to older therapies. It may also be investigated for use in restless legs syndrome due to its dopaminergic activity. Its design supports better blood-brain barrier penetration, enhancing central nervous system effects.